Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.41 |
| ▸ | CNR1 | P21554 | 15/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23502551 | 0.93 | CNR2 (0.38) | CNR2CNR1GPR55KDM4ETP53 | |
| SCHEMBL20047666 | 0.93 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL20047612 | 0.93 | CNR2 (0.45) | CNR2CNR1 | |
| SCHEMBL23502431 | 0.92 | CNR2 (0.34) | CNR2CNR1 | |
| SCHEMBL20047720 | 0.88 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL20047682 | 0.85 | CNR2 (0.37) | CNR2CNR1 | |
| SCHEMBL23502571 | 0.82 | TLR7 (0.32) | CNR2 | |
| SCHEMBL20047607 | 0.81 | CNR2 (0.36) | CNR2CNR1 | |
| SCHEMBL20047602 | 0.79 | CNR2 (0.33) | CNR2CNR1 | |
| SCHEMBL21161526 | 0.78 | CNR2 (0.38) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CNR2 485/4885CNR1 410/4885GPR55 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.